Sevinc Sultan Acar, Cinar Ayse Surhan, Basi Nermin Balta, Metin Seyhan, Yucel Tugba, Islamoglu Serkan, Altinay Mustafa, Ozdemir Haci Mustafa
Department of Anesthesiology and Reanimation, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Department of Orthopedics, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Sisli Etfal Hastan Tıp Bul. 2022 Jun 28;56(2):189-195. doi: 10.14744/SEMB.2021.35902. eCollection 2022.
The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19.
Data were collected retrospectively between March 10 and May 10, 2020, from patients' records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir.
A total of 100 patients' data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9-24) days with favipiravir and 8.5 (5-12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5-15) days and 4 (3-9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001).
The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed.
本研究旨在比较接受法匹拉韦和洛匹那韦 - 利托那韦治疗的新冠肺炎患者在重症监护病房（ICU）的死亡率及总体医院死亡率。
回顾性收集2020年3月10日至5月10日期间因新冠肺炎入住ICU患者的病历数据。比较接受法匹拉韦和洛匹那韦 - 利托那韦治疗患者的实验室数据、临床特征、ICU及医院死亡率、ICU及医院住院时长。
共调查了100例患者的数据。85%的患者接受法匹拉韦治疗，其余患者接受洛匹那韦 - 利托那韦治疗。两个抗病毒治疗组的临床和实验室数据相似。法匹拉韦组的住院时长为16（9 - 24）天，洛匹那韦 - 利托那韦组为8.5（5 - 12.5）天（p = 0.002）。法匹拉韦组和洛匹那韦 - 利托那韦组的ICU住院时长分别为8（5 - 15）天和4（3 - 9）天（p = 0.011）。法匹拉韦组的ICU死亡率为65.9%，洛匹那韦 - 利托那韦组为80%（p = 0.002）。法匹拉韦组和洛匹那韦 - 利托那韦组的医院死亡率分别为67.1%和80%（p = 0.001）。
接受法匹拉韦治疗患者的死亡率低于接受洛匹那韦 - 利托那韦治疗的患者。法匹拉韦的效果有待更多关注和试验来证实。
